Nanmo Biotech announced that it expects revenue of 216 million yuan to 250 million yuan in the first half of 2026, up 10.34%-27.71% year on year; net profit to mother is estimated to be 8 million yuan to 10 million yuan, down 55.97%-44.96% from 18.1674 million yuan in the same period in 2025. The decline in net profit is mainly due to a sharp increase in share payment fees for the current period compared to the same period in 2025, and the share payment amount was reduced during the same period in 2025 due to the limited stock incentive plan not meeting the expected performance standards; after deducting the impact of share payments, net profit to mother is estimated to be 13 million yuan to 15.8 million yuan, an increase of 47.27%-78.99% over the previous year. This performance forecast has not been audited.

Nanmo Biotech announced that it expects revenue of 216 million yuan to 250 million yuan in the first half of 2026, up 10.34%-27.71% year on year; net profit to mother is estimated to be 8 million yuan to 10 million yuan, down 55.97%-44.96% from 18.1674 million yuan in the same period in 2025. The decline in net profit is mainly due to a sharp increase in share payment fees for the current period compared to the same period in 2025, and the share payment amount was reduced during the same period in 2025 due to the limited stock incentive plan not meeting the expected performance standards; after deducting the impact of share payments, net profit to mother is estimated to be 13 million yuan to 15.8 million yuan, an increase of 47.27%-78.99% over the previous year. This performance forecast has not been audited.